In a more comparable study, Konsti et al (2011) reported that automated assessment of Ki-67 proliferative activity had prognostic value in 1334 breast cancer patients, but did not examine the survival relationships in the subgroup of patients who received Tamoxifen. This evidence concerns the gene MKI67 and breast cancer.